Literature DB >> 27339643

Late effects of chemotherapeutic agents on renal function in childhood cancer survivors: a review of the literature.

D O'Sullivan1.   

Abstract

BACKGROUND: Survival outcomes for childhood cancers have significantly improved. As more children are now surviving into adulthood, knowledge of the long-term effects of childhood cancer treatments has become the focus of research. AIM: To determine what is known about the incidence of renal function impairment in childhood cancer survivors and to determine what is known about risk factors for developing renal function impairment following childhood cancer treatment.
METHODS: A comprehensive literature search was preformed to identify studies that investigated renal dysfunction in patients who were diagnosed with childhood cancer and treated with potentially nephrotoxic chemotherapeutic agents. Potentially nephrotoxic chemotherapeutic agents identified in the selection criteria include ifosfamide, cisplatin, carboplatin and methotrexate.
RESULTS: 15 papers met the inclusion criteria. Renal function impairment was reported in 15 of 15 studies included in this literature review. The incidence of ifosfamide induced nephrotoxicity varied from 1 to 50 %. This variation may be due to the heterogeneity of reported outcome measurements. Treatment with cisplatin and carboplatin was associated with hypomagnesemia. The prevalence of hypomagnesemia varied from 7 to 29 %. This variation may be due to diversity of treatment protocols. The incidence of renal dysfunction following treatment with methotrexate was reported as 1.8 % and completely reversible.
CONCLUSION: As more childhood cancer survivors are reaching adulthood, a new niche of cancer research has emerged. Researchers are now investigating the late effects due to cytotoxic treatments. Renal function impairment is a potential late effect of treatment with nephrotoxic chemotherapeutic agents including ifosfamide, cisplatin, carboplatin and methotrexate.

Entities:  

Keywords:  Carboplatin; Childhood cancer survivors; Cisplatin; Ifosfamide; Late effects; Methotrexate

Mesh:

Substances:

Year:  2016        PMID: 27339643     DOI: 10.1007/s11845-016-1473-z

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  17 in total

Review 1.  Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group.

Authors:  Deborah P Jones; Sheri L Spunt; Daniel Green; James E Springate
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

Review 2.  Cisplatin and hypomagnesemia.

Authors:  H Lajer; G Daugaard
Journal:  Cancer Treat Rev       Date:  1999-02       Impact factor: 12.111

3.  Cisplatin therapy in childhood: renal follow up 3 years or more after treatment. Swiss Pediatric Oncology Group.

Authors:  N X von der Weid; B M Erni; C Mamie; H P Wagner; M G Bianchetti
Journal:  Nephrol Dial Transplant       Date:  1999-06       Impact factor: 5.992

4.  Partial reversibility of cisplatin nephrotoxicity in children.

Authors:  P R Brock; D E Koliouskas; T M Barratt; E Yeomans; J Pritchard
Journal:  J Pediatr       Date:  1991-04       Impact factor: 4.406

5.  Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.

Authors:  R Loebstein; G Atanackovic; R Bishai; J Wolpin; S Khattak; G Hashemi; M Gobrial; S Baruchel; S Ito; G Koren
Journal:  J Clin Pharmacol       Date:  1999-05       Impact factor: 3.126

6.  Long-term follow-up of renal function after high-dose methotrexate treatment in children.

Authors:  Marika H Grönroos; Timo Jahnukainen; Merja Möttönen; Mikko Perkkiö; Kerttu Irjala; Toivo T Salmi
Journal:  Pediatr Blood Cancer       Date:  2008-10       Impact factor: 3.167

7.  Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.

Authors:  Roderick Skinner; Annie Parry; Lisa Price; Michael Cole; Alan W Craft; Andrew D J Pearson
Journal:  Eur J Cancer       Date:  2009-10-21       Impact factor: 9.162

8.  Late effects surveillance system for sarcoma patients.

Authors:  Thorsten Langer; Wolfgang Stöhr; Stefan Bielack; Michael Paulussen; Jörn Treuner; Jörn D Beck
Journal:  Pediatr Blood Cancer       Date:  2004-04       Impact factor: 3.167

9.  Dose-related nephrotoxicity of carboplatin in children.

Authors:  M W English; R Skinner; A D Pearson; L Price; R Wyllie; A W Craft
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

10.  Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.

Authors:  R Skinner; S J Cotterill; M C Stevens
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

View more
  5 in total

1.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11

2.  Lifetime Costs of Surviving Cancer-A Queensland Study (COS-Q): Protocol of a Large Healthcare Data Linkage Study.

Authors:  Katharina M D Merollini; Louisa G Gordon; Joanne F Aitken; Michael G Kimlin
Journal:  Int J Environ Res Public Health       Date:  2020-04-20       Impact factor: 3.390

3.  Dietary Acid Load, Serum Polychlorinated Biphenyl Levels, and Mortality Following Breast Cancer in the Long Island Breast Cancer Study Project.

Authors:  Briana N C Chronister; Tianying Wu; Regina M Santella; Alfred I Neugut; Mary S Wolff; Jia Chen; Susan L Teitelbaum; Humberto Parada
Journal:  Int J Environ Res Public Health       Date:  2021-12-30       Impact factor: 3.390

4.  Ifosfamide as a Cause of Fanconi Syndrome.

Authors:  Daniel Martinez; Joaquin Rodelo; Sebastian Pelaez García
Journal:  Cureus       Date:  2022-03-01

5.  Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors.

Authors:  Eryk Latoch; Katarzyna Konończuk; Katarzyna Taranta-Janusz; Katarzyna Muszyńska-Rosłan; Edyta Szymczak; Anna Wasilewska; Maryna Krawczuk-Rybak
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-14       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.